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Abstract
Background: Procalcitonin (PCT) is an inflammatory marker that has been used as indicator of
severe bacterial infection. We evaluated the concentrations of PCT as a marker for systemic
infection compared to C-reactive protein (CRP) in patients neutropenic febrile.
Methods: 52 adult patients were enrolled in the study. Blood sample was collected in order to
determine the serum concentrations of PCT, CRP and other hematological parameters at the
onset of fever. The patients were divided into 2 groups, one with severe infection (n = 26) and the
other in which the patients did not present such an infection (n = 26). Then PCT and CRP
concentrations at the fever onset were compared between groups using non parametric statistical
tests, ROC curve, sensitivity, specificity, likelihood ratio, and Spearman's correlation coefficient.
Results: The mean of PCT was significantly higher in the group with severe infection (6.7 ng/mL
versus 0.6 ng/mL – p = 0.0075) comparing with CRP. Serum concentrations of 0.245 ng/mL of PCT
displayed 100% de sensitivity and 69.2% specificity. PCT concentrations of 2,145 ng/mL presented
a likelihood ratio of 13, which was not observed for any concentration of CRP.
Conclusion: PCT seems to be an useful marker for the diagnosis of systemic infection in febrile
neutropenic patients, probably better than CRP.
Background
Patients suffering from malignant hematological diseases
present long periods of profound neutropenia which are a
result of chemotherapy and of other factors associated to
the disease. During this neutropenic state, the risk of
infection is high [1]. The morbidity and mortality associ-
ated to infection acquired after aggressive chemotherapy
remain the greatest clinical problem suffered by these
patients. Considering that fever in neutropenic patients is
an emergency condition, that there is initially a paucity of
clinical information and that obtaining results for micro-
biological tests may take considerable time, a new clinical
laboratory test that would assist the physician in decision
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making as to the therapeutic conduct to be adopted in
such cases would be invaluable.
Two such laboratory parameters that fit this purpose are
C-reactive protein (CRP) and interleukin-6 (IL-6) [2]. CRP
is an acute phase protein used mostly for as a biochemical
inflammatory marker in cancer, however, its concentra-
tion does not significantly increase until 24 to 48 hours
after the onset of inflammation. Serum concentrations of
CRP are proportional to the degree of tissue damage and
the activity of the basal malignant disease [3-6]. IL-6 con-
centration presents a low specificity and furthermore, its
determination is costly [6].
Procalcitonin (PCT) is a peptide composed of 116 ami-
noacids, also known as the prohormone of calcitonin,
and is well documented that its concentration increases in
patients with bacterial meningitis or sepsis, however, its
main lieu of synthesis and its function have not been fully
elucidated yet [7-12].
The association of PCT high concentration with infection
may be useful for diagnosis patients with febrile neutrope-
nia, especially in those with systemic infections, and this
supports the need of evaluating PCT as a marker for severe
systemic infection and to compare it to CRP, which is cur-
rently the most used marker for this purpose.
Methods
In order to determine whether PCT can be used as a
marker for bacterial infection in febrile neutropenic
patients, a cohort study was drawn up, composed of a
sequential convenience sample of 52 adult inpatients
with neutropenia hospitalized at the Hematology Infir-
mary at the Hospital das Clínicas of the Faculty of Medi-
cine at the University of São Paulo, from August 2004 to
September 2006. All patients enrolled in the study suf-
fered from a malignant hemopathy, were severely neutro-
penic, either due to chemotherapy, or as a consequence of
the disease and all patients were febrile.
Neutropenia was defined as a neutrophil count of less
than 500/mm3 or less than 1,000/mm3 with an expected
decline to 500/mm3 [1]. Fever was defined as a single
body temperature peak over 38.3°C or a sustained body
temperature of more than 38.0°C for over 1 hour, not
being a consequence of the administration of blood-
derived products [1].
Patients whose febrile states were clearly associated to the
infusion of blood-derived products were excluded from
the study as were those who had received antibiotic ther-
apy during a 12 hour period immediately before the col-
lection of a blood sample for use in the study.
With the diagnosis of a febrile state, 3 to 5 mL of blood
were collected from patients participating in the study by
forearm venipuncture or from a central venous catheter.
The blood was collected in dry tubes and was then centri-
fuged for 15 minutes at 3400 rpm up to 60 minutes after
collection. The serum obtained from each sample was
stored at -20°C until the moment of analysis.
All patients were evaluated as to the existence of a site of
infection using clinical and microbiological data when
they developed fever and received antimicrobial therapy
according to the standard procedure used for patients with
febrile neutropenia [1].
The criteria used for the diagnosis of infection and colo-
nizers were those according to the CDC [13]. The diagno-
sis of Coagulase negative Staphylococcus (CoNS)
bacteremia was considered when a patient presented mul-
tiple isolates presenting the same antimicrobial suscepti-
bility profile from at least 2 different blood cultures
collected at different time periods. Sepsis was defined as
SIRS (systemic inflammatory response syndrome) with
clinical signs of any underlying infection with or without
growing microorganisms from any culture of any biologi-
cal fluid [13]. Severe sepsis was considered when fever was
accompanied by signs of tissue hyperperfusion such as
oliguria, metabolic acidosis or deterioration of the level of
consciousness [14]. Fever of Undetermined Origin (FUO)
was considered when no cause of fever could be estab-
lished after three days of hyperthermia [15].
A complete clinical follow-up was carried out for each
patient from the onset of neutropenia until clinical reso-
lution (death or discharge), by means of a standardized
clinical and laboratory data file. This system had the
objective of classifying the patients into groups according
to diagnosis of infection. The clinical data recorded were
physical signs, hematology and chemistry parameters,
results of blood, urine and tissue secretion cultures, radi-
ographs and CT scans of the thorax, paranasal sinuses and
abdomen, when necessary.
The patients were classified clinical and microbiologic cri-
teria into one of these two groups:
Group 1 – Patients with severe infection (fever + positive
blood culture for bacteria or fungi) or clinical signs of sep-
sis as well as patients with a proven fungal infection, n =
26.
Group 2 – Patients with FUO, with or without a known
colonizer, or localized bacterial infection in a single site
(for instance: abscess, pneumonia, skin), as proven by a
complementary test.BMC Infectious Diseases 2007, 7:137 http://www.biomedcentral.com/1471-2334/7/137
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Data interpretation
The correlation between clinical condition and PCT con-
centration of was considered according to the following
criteria proposed by Giamarellou et al. (2004) [12]:
[PCT] < 0.5 ng/mL – Fever of Undetermined Origin
(FUO)
0.5 ng/mL ≤ [PCT] < 1.0 ng/mL – Localized infection
1.0 ng/mL ≤ [PCT] < 5.0 ng/mL – Bacteremia or probable
sepsis
[PCT] ≥ 5.0 ng/mL – Severe sepsis
Blood samples for PCT and CRP analysis were collected
either before or up to 12 hours after the initiation of anti-
microbial therapy.
PCT determination
Serum concentrations of PCT were determined in dupli-
cate by an immunoluminometric assay (Brahms, PCT-
LIA, Berlin, Germany) that demands only 20 μL of serum
as sample. The lowest concentration of PCT detectable by
this technique is 0.08 ng/mL.
CRP determination
The quantitative determination of CRP was carried out
using a kit based on nephelometry (Dade-Behring N High
Sensitivity CRP). The reference range for normal individ-
uals supplied by the kit manufacturer is ≤3, 5 mg/L.
Statistical analysis
The levels of PCT and CRP were compared between the 2
groups. Statistical analysis was carried out using Student's
t-test for parametric or Mann-Whitney test for medians of
non parametric data and Fischer's Exact Test for the com-
parison of proportions. The Spearman's correlation coef-
ficient between PCT and CRP was calculated for each
group. The sensitivity, specificity, positive and negative
predictive values, the likelihood ratio and the area under
the ROC (Receiver Operator Characteristic) curve were
calculated for both PCT and CRP.
Finally, a Wald Backward Stepwise Logistical Regression
Analysis for multiple variables was carried out using as
independent variables the concentrations of PCT, PCR,
granulocyte and platelet count, and using as a dependent
variable in the first analysis the presence of systemic infec-
tion and in the second analysis the outcome of death. The
values were calculated with the respective 95% confidence
intervals and a level of significance of α = 5%. For statisti-
cal analysis the data was stored in an MS-Excel® 2003
spreadsheet and later processed using the software Instat®
and Prism4® Graphpad and SPSS® version 12.0[16,17].
Results
The distribution of patients as to sex, age, recentness of
diagnosis versus re-incidence or non-responsiveness of
disease, granulocyte and platelet count, and hemoglobin
concentration were homogeneous throughout both
groups. The mean age was of 40.8 ± 16.0 years in the
group with severe infection (group 1) and 40.0 ± 18.4 in
the group without severe infection (group 2). The sex ratio
in each group was 65.4% and 73.1% of males in group 1
and group 2, respectively. As to the presence of recent
diagnosis we observed 73.1% and 65.4% for both groups,
respectively. For groups 1 and 2 the mean granulocyte
counts were 77 ± 137/mm3 and 86 ± 140/mm3, respec-
tively, the mean platelet counts were 37,961 ± 28,593/
mm3 and 35,962 ± 21,510/mm3, and the mean hemo-
globin concentrations were 8.0 ± 2.4 g/dL and 8.5 ± 1.6 g/
dL, respectively. The frequency of deaths associated to the
febrile episodes for group 1 were of 11/26 and 2/26 for
group 2 (p = 0.009). All patients were suffering from
malignant hemopathies. Amongst the diagnoses were
acute leucoses (40/52), chronic myelomonocytic leuke-
mia (2/52), Hodgkin's Lymphoma (1/52) and non-Hodg-
kin Lymphoma (9/52). The infectious diagnoses of each
patient can be seen in Table 1. Seventy three blood cul-
tures were positive among the neutropenic febrile
patients, Gram-negative was the most frequent agent iso-
lated responsible for 38 (54%) of positive cultures fol-
lowed by Gram-positive 34(48%) and fungi 1 (1.4%).
Among the Gram-negative the most frequent agents iden-
tified were Enterobacter aerogenes (36%) and Klebsiella
pneumoniae (30%) and among Gram-positive, coagulase
negative Staphylococcus was responsible for 28 (82%) of
positive blood culture. Two lung cultures and 01 urine
Table 1: Infectious diagnosis of the 52 febrile neutropenic 
patients.
Diagnosis Number of patients (%)
FUO* with known contaminant 4(7,7)
FUO without known contaminant 14(26,9)
UTI** 1(1,9)
Cellulitis (soft tissue infection) 1(1,9)
Catheter infection 1(1,9)
Pseudomembranous colitis and 
soft tissue infection
1(1,9)
Neutropenic colitis 1(1,9)
Pneumonia 2(3,8)
Dental abscess 1(1,9)
Pulmonary cryptococcosis 1(1,9)
Bloodstream infection 5(9,6)
Sepsis or severe sepsis 12(23,1)
Septic shock 2(3,8)
Septic shock and MOF*** 6(11,6)
Total 52(100,0)
*FUO: Fever of Undetermined Origin; **UTI: Urinary Tract Infection ; 
***MOF: Multiple Organ Failure.BMC Infectious Diseases 2007, 7:137 http://www.biomedcentral.com/1471-2334/7/137
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culture was positive respectively for S. aureus and Crypto-
coccus neoformans and Acinetobacter baumannii. The con-
centrations of PCT and CRP in neutropenic febrile adults
with severe infection (group 1) and without severe infec-
tion (group 2) can be seen in Table 2.
As can be seen in tables 3 and 4, serum levels of 0.245 ng/
mL (≈0.5) of PCT are able to identify 100% of the febrile
neutropenic patients with systemic infection and enabled
to discard of almost one third of the patients without
severe systemic infection.
In these tables, the likelihood ratio is also different
between PCT and CRP, which suggests that among
patients who present PCT concentrations of 2.145 ng/mL,
the chance of a systemic infection occurring is of 13 to 1,
whilst no probability of this magnitude was observed for
different cut-off levels or CRP.
Figures 1 and 2 show that the medians and dispersion of
PCT and CRP concentrations were statistically differents
in patients with and without systemic infection. There was
no correlation between serum levels of PCT and CRP, as
can be seen in figure 3, in both groups with and without
systemic infection. This was confirmed by the Spearman
Correlation Coefficient that failed to indicate statistical
significance in both groups.
The ROC curves for PCT for the diagnosis of infection and
prognosis can be seen in figure 4. The area under the curve
is substantially different between PCT and CRP.
Calculated a posteriori, considering the sample size of 52
patients (two groups of 26), the observed areas under the
ROC curve of 79.1% for PCT and of 50.0% for CRP and
the Spearman (rank) coefficients between PCT and CRP of
0.07 for Group 1 and of 0.08 Group 2, the power of the
test (1 - β) was of 0.80 to discriminate the areas difference.
The only independent variable that remained associated
to severe infection in the Wald Backward Stepwise Multi-
variate Logistic Regression model was PCT (OR = 2.49;
95% CI = 1.18–5.27; p = 0.016).
In the prognosis model of Multivariate Logistic Regres-
sion, the only significant association observed with death
was the platelet count (OR = 1.0; 95% CI = 1.0–1.0; p =
0.031).
Discussion
Febrile neutropenia is a medical emergency that calls for a
precocious diagnosis and the administration of antibiot-
ics as soon as possible. The patient's clinical, microbio-
logical and radiological data usually fail in revealing the
origin of the fever. Even though it is known that PCT is
also produced to some extent by leukocytes [18], studies
have shown that PCT may be useful as a marker in neutro-
penic patients [7,8,12,19,20]. Al Nawas et al. (1996) have
shown that PCT is increased in 25 patients with neutrope-
nia and sepsis [8]. Giamarellos-Bourboulis et al., in a pro-
spective study with 115 febrile neutropenic adults,
revealed that PCT might be a useful diagnostic tool for the
early detection of a systemic infection in this population
[7].
In our study the following variables: sex, age, recentness of
diagnosis versus re-incidence or non-responsiveness of
disease, granulocyte and platelet count and hemoglobin
concentration were similar between groups (p > 0.05).
The rates of death related to the febrile event was shown
to be strikingly different between both groups, with 11
deaths in group 1 (systemic infection) in contrast to only
2 deaths in group 2 (p = 0.009). As to the basal hemopa-
thies, over 2/3 of all patients were suffering from some
form of leukemia.
The most common causes of fever in our patients were
FUO, followed by sepsis. The most frequently isolated
microorganisms were Staphylococcus sp. followed by
Enterobacter sp. and Klebsiella sp.
In spite of the sample size (n = 52) and of the single deter-
mination of PCT at the onset of fever, the increased values
of PCT were able to indicate infection already on the first
day of fever in group 1. These neutropenic patients with
severe infection (diagnosed clinically and/or microbio-
logically) presented high concentrations of PCT, but CRP
concentrations evinced no correlation with severe infec-
tion.
Table 2: Procalcitonin (PCT) and C-reactive protein (CRP) concentrations in adult febrile neutropenic patients according to presence 
or absence of systemic infection.
Markers Group with severe systemic 
infection (n = 26)
Group without systemic 
infection (n = 26)
Ststistical Significance
PCT(ng/mL) median (min-max) 2,30 (0,27–50,96) 0,49 (0,08–2,15) P = 0,0003(Sig)*
CRP(mg/L) median (min-max) 101,5 (5,2–341,0) 87,8 (19,5–546,0) P = 0,9198(NS)*
* Mann-Whitney testBMC Infectious Diseases 2007, 7:137 http://www.biomedcentral.com/1471-2334/7/137
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The mean PCT concentrations were statistically different
between both groups already at the beginning of the
febrile state, with PCT being much more elevated among
patients with severe infection. This was not observed in
the serum concentrations of CRP. For patients with neu-
tropenia who did not have systemic infection (group2),
that is, those who were diagnosed with FUO or localized
infection presented low concentrations of PCT
(0,08–2,15) that were highly significant (p = 0,0003) and
CRP concentrations that did not greatly differ statistically
from those found in group 1 (19,5–546,0) (p = 0,9198).
It can be seen in these cases that there is no correlation
between PCT and CRP, that is, the variations in PCT con-
centration are not concomitant with the variations in CRP
and the results further indicate that the PCT concentra-
tions change more precociously than those of CRP in
response to an infection. Also, there is no correlation
between PCT versus PCR values in the group without sys-
temic infection. Because PCT concentration changes more
rapidly than CRP in response to infection (bacterial and/
or fungal), a diagnostic decision can be taken more preco-
ciously, which would aid in speeding up choosing the
therapeutic conduct.
It can be seen, from the ROC curve, that CRP cannot be
used as a diagnostic or prognostic marker in febrile neu-
tropenia. The area under the ROC curve for PCT is of 79%
(CI between 67% and 91%), in contrast to 50% for CRP
(CI between 34% and 67%) for diagnosing systemic infec-
tion in the groups studied.
Table 3: Verosimilarity ratio (VR) of different cut-off points of procalcitonin (PCT) concentration for the diagnosis of systemic 
infection in patients with febrile neutropenia.
 [PCT] ng/mL With systemic infection 
(sensitivity)
Without systemic infection 
(1 - specificity)
Likelihood ratio* (95% CI)
0,245 26
100%
18
69,2%
1,44 (Incalculable*)
0,275 24
92,3%
18
69,2%
1,33 (1,01 to 1,76)
0,490 22
84,6%
13
50,0%
1,69 (1,11 to 1,76)
1,160 15
57,7%
4
15,4%
3,75 (1,44 to 9,79)
1,730 14
53,8%
2
7,7%
7,00 (1,76 to 27,78)
2,145 13
50,0%
1
3,8%
13,00 (1,83 to 92,29)
2,390 13
50,0%
0
0%
(Incalculable*)
TOTAL 26
100,0%
26
100,0%
* Impossible to calculate, for the values of sensitivity or of 1 - specificity correspond to 100% of the sample with or without the disease.
Table 4: Verosimilarity ratio (VR) of different cut-off points of C-reactive protein (CRP) concentration for the diagnosis of systemic 
infection in patients with febrile neutropenia.
[CRP] mg/L Group with systemic 
infection (n = 26)
Group without systemic 
infection (n = 26)
Likelihood ratio (95% CI)
21,30 23
88,5%
25
96,2%
0,92 (0,79 to 1,08)
40,00 18
69,2%
24
92,3%
0,75 (0,56 to 0,99)
72,00 16
61,5%
15
53,8%
1,07 (0,68 to 1,67)
140,00 11
42,3%
7
26,94%
1,57 (0,72 to 3,41)
173,00 5
19,2%
4
15,4%
1,25 (0,38 to 4,14)
214,50 1
3,8%
1
3,8%
1,00 (0,06 to 15,15)
TOTAL 26
100,0%
26
100,0%BMC Infectious Diseases 2007, 7:137 http://www.biomedcentral.com/1471-2334/7/137
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Giamerellou et al. clearly showed in an important multi-
centre study concerning febrile neutropenia that PCT lev-
els were elevated significantly in patients with severe
sepsis compared to bacteremia (n = 158) [12]. A PCT cut-
off value of 1.0 ng/mL could indicate bacteraemia, while
severe sepsis could be shown with a level over 5.0 ng/mL.
In this present study, the cut-off points used for PCT were
0.25 ng/mL; 0.5 ng/mL, 1.0 ng/mL and 2.0 ng/mL. Using
values of 0.25 ng/mL, it was possible to discriminate
between presence or absence of systemic infection with a
sensitivity of 100% and a specificity of 30.8%. When the
cut-off point used was of 0,49 ng/mL, the sensitivity and
specificity obtained were of 85% and 50%, respectively.
There were no satisfactory cut-off values for CRP.
The PCT ROC curves for evolution to death as a result of
systemic infection limit an area under the curve statisti-
cally different than that expected by chance, whereas this
is not the case for CRP. Furthermore, specifically for infec-
tion, one can see by means of the confidence intervals that
Comparison between the procalcitonin (PCT) and C-reac- tive protein (CRP) ROC curves in febrile neutropenic  patients, according to death* related to the febrile event as  an outcome Figure 4
Comparison between the procalcitonin (PCT) and C-reac-
tive protein (CRP) ROC curves in febrile neutropenic 
patients, according to death* related to the febrile event as 
an outcome. *Deaths: 13. *Not Deaths: 39. 1 - specificity. 
**significant. PCT – area under the curve: 70.8% (95% CI: 
50.9 to 90.7)**. PCR – area under the curve: 57.8% (95% CI: 
38.4 to 77.2)
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there is a statistically significant difference between the
PCT ROC curve and the CRP ROC curve. The main prob-
lem as to the determination of PCT is the ample variation
of the results obtained that do not follow a Gaussian dis-
tribution, which thus makes it more difficult to determine
a cut-off point with an optimum sensitivity and specificity
adequate enough to indicate an infection. These data cor-
roborate those obtained by Giamarellos-Bourboulis et al.
(2001), who also found this distribution [7]. Even though
a PCT concentration that fulfills adequate sensitivity and
specificity and considering that a sensitivity of 73% has
been proposed by other authors as satisfactory for PCT
[7,21], we could assume that concentrations of 0.49 ng/
mL, or better 0.5 ng/ml, with 85% sensitivity and 50%
specificity might be useful for the differential diagnosis
between a disseminated infection (bacteremia, sepsis and
its intermediate stages) and a non disseminated infection
(FUO and localized infection).
Cut-off values of more than 2,0 ng/mL, which are sug-
gested by the manufacturer for immunocompetent
patients would increase the specificity to 96.2%, however,
the sensitivity would drop to 53%, which would imply
that a severe infection might not be considered in 1 of
each 2 really infected patients. As the PCT concentrations
rise, sensitivity decreases and specificity increases, to the
point which leads us to assume that values >2.0 ng/mL in
a single patient might indicate severe sepsis.
Using logistical regression, only PCT remained in the
model as associated to the presence of severe infection.
Thus, CRP concentration was not able to distinguish
between presence or absence of a disseminated infection,
perhaps because of the contribution of the basal malig-
nant disease to the production of CRP [22]. Recently,
Schuttrumpf et al. evaluated PCT plasma concentrations
prospectively in 111 patients with a hemato-oncological
condition with a CRP concentration >8 mg/L. Median
CRP concentrations did not differ significantly between
groups of patients with and without infection. However,
PCT concentrations were higher in patients with infection
than in those without infection and contributed signifi-
cantly to the differential diagnosis of elevated CRP con-
centrations in patients with hemato-oncological
conditions [23].
The prognostic significance of PCT has already been dem-
onstrated in studies with immunocompetent adult
patients in intensive care units [24] and in children with
febrile neutropenia [25]. A recent study evaluated 49 chil-
dren, who had 60 febrile episodes compared follow-up
value of PCT with CRP in documenting the infection in
neutropenic febrile patients. PCT and CRP levels were sig-
nificantly higher in neutropenic febrile patients with
infection than in control patients (P < 0.001). In sequen-
tial analyses of patients without documented infections,
the median of PCT concentrations shows a tendency to
fall after the 8th hour of onset of fever, whereas in patients
with documented infections PCT concentrations fell after
the 48th hour. This study suggests that PCT, when meas-
ured periodically, is a more useful diagnostic inflamma-
tion parameter in pediatric neutropenic-fever patients
than CRP [26].
In our study, when we evaluated prognosis, its association
with platelet count, even though significant from a statis-
tical point of view, is not useful taking into account that it
does not present a large increase of the probability of
death as an outcome.
Although Giamarellou et al (2004) found a area under the
ROC curve of 71%, very close to the one of these study,
the present data suggest a lower cut-off value for PCT (0.5
ng/mL) could distinguish infected neutopenic febrile
patients from those without severe systemic infection.
Conclusion
PCT concentration was markedly associated with the diag-
nosis of severe infection in patients with febrile neutrope-
nia, in contrast with CRP whose concentration was so
useful to distinguish between presence and absence of a
disseminated infection. None of the other variables of the
study could be correlated to prognosis.
Further studies, with larger samples, involving PCT con-
centration curves and with and more homogeneous
groups of febrile severely neutropenic patients should be
carried out in other centers in order to confirm our results.
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